TY - JOUR
T1 - Whole-genome sequencing of 490,640 UK Biobank participants
AU - The UK Biobank Whole-Genome Sequencing Consortium
AU - Illumina
AU - UK Biobank
AU - Sanger (Velsera Seven Bridges)
AU - Johnson & Johnson
AU - GSK
AU - Amgen deCode genetics
AU - AstraZeneca
AU - Manuscript Writing Group
AU - Schulz-Trieglaff, Ole
AU - Mehio, Rami
AU - Young, Alan
AU - Carson, Lauren
AU - Watson, Rachel
AU - Fry, Daniel
AU - Welsh, Samantha
AU - Burkitt-Gray, Lucy
AU - Clark, Caroline
AU - Pancholi, Mahesh
AU - Sheard, Simon
AU - Sellors, Jonathan
AU - Allen, Naomi
AU - Effingham, Mark
AU - Collins, Rory
AU - Langford, Cordelia
AU - Rance, Richard
AU - Gray, Emma
AU - Smerdon, Natalie
AU - Grout, Laura
AU - Ellis, Peter
AU - Thurston, Scott
AU - Shirley, Lesley
AU - Quail, Michael
AU - Redshaw, Nicholas
AU - Aigrain, Louise
AU - Lazarevic, Mladen
AU - Slavkovic-Ilic, Marijeta
AU - Lenhardt Ackovic, Lea
AU - Miletic, Nevena
AU - Wright, Sean
AU - Williams, Mia
AU - Wells, Eloise
AU - Wells, Alan
AU - Weldon, Danni
AU - Voak, Paul
AU - Vancollie, Valerie
AU - Trigg, Elliott
AU - Tovar Corona, Jaime M.
AU - Taylor, Sam
AU - Taylor, Oprah
AU - Still, Ian
AU - Squares, Jan
AU - Sloper, Lisa
AU - Popov, Alexandru
AU - Pardubska, Barbora
AU - Morrow, Leanne
AU - Monteiro, Ana
AU - Jackson, David K.
AU - Lythgow, Kieren
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/9/18
Y1 - 2025/9/18
N2 - Whole-genome sequencing provides an unbiased and complete view of the human genome and enables the discovery of genetic variation without the technical limitations of other genotyping technologies. Here we report on whole-genome sequencing of 490,640 UK Biobank participants, building on previous genotyping effort1. This advance deepens our understanding of how genetics associates with disease biology and further enhances the value of this open resource for the study of human biology and health. Coupling this dataset with rich phenotypic data, we surveyed within- and cross-ancestry genomic associations and identified novel genetic and clinical insights. Although most associations with disease traits were primarily observed in individuals of European ancestries, strong or novel signals were also identified in individuals of African and Asian ancestries. With the improved ability to accurately genotype structural variants and exonic variation in both coding and UTR sequences, we strengthened and revealed novel insights relative to whole-exome sequencing2,3 analyses. This dataset, representing a large collection of whole-genome sequencing data that is available to the UK Biobank research community, will enable advances of our understanding of the human genome, facilitate the discovery of diagnostics and therapeutics with higher efficacy and improved safety profile, and enable precision medicine strategies with the potential to improve global health.
AB - Whole-genome sequencing provides an unbiased and complete view of the human genome and enables the discovery of genetic variation without the technical limitations of other genotyping technologies. Here we report on whole-genome sequencing of 490,640 UK Biobank participants, building on previous genotyping effort1. This advance deepens our understanding of how genetics associates with disease biology and further enhances the value of this open resource for the study of human biology and health. Coupling this dataset with rich phenotypic data, we surveyed within- and cross-ancestry genomic associations and identified novel genetic and clinical insights. Although most associations with disease traits were primarily observed in individuals of European ancestries, strong or novel signals were also identified in individuals of African and Asian ancestries. With the improved ability to accurately genotype structural variants and exonic variation in both coding and UTR sequences, we strengthened and revealed novel insights relative to whole-exome sequencing2,3 analyses. This dataset, representing a large collection of whole-genome sequencing data that is available to the UK Biobank research community, will enable advances of our understanding of the human genome, facilitate the discovery of diagnostics and therapeutics with higher efficacy and improved safety profile, and enable precision medicine strategies with the potential to improve global health.
UR - https://www.scopus.com/pages/publications/105016650839
U2 - 10.1038/s41586-025-09272-9
DO - 10.1038/s41586-025-09272-9
M3 - Article
C2 - 40770095
AN - SCOPUS:105016650839
SN - 0028-0836
VL - 645
SP - 692
EP - 701
JO - Nature
JF - Nature
IS - 8081
ER -